リコンビナントタンパク質
ACROBiosystems社 プロダクトリスト:Recombinant Protein
- サプライヤー
- AcroBioSystems
- カタログNo.
- HL1-H82T3
- 製品名称
- Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS verified)
- タンパク質名
- HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)
- Species
- Human
- HOST
- HEK293
Overview
Synonyms | - |
---|---|
Characteristics | Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. This protein carries a flag tag at the C-terminus, followed by an Avi tag (Avitag?). The protein has a calculated MW of 35.9 kDa and 13.8 kDa. The protein migrates as 43-46 kDa and 12 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Endotoxin Level | 1.0 EU per μg |
Purity | 90% |
Description | NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1. |
Reference | - |
URL | https://www.acrobiosystems.com/P6879-Biotinylated-Human-HLA-A%2A02%3A01B2MNY-ESO-1-%28SLLMWITQV%29-Complex-Protein-%28Monomer-MALS-verified%29.html |